Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Use Of Lenalidomide In Patients With Multiple Myeloma Having Already Received At Least Two Previous Therapies Approved By NICE, UK
A review of the NICE decision on the approval of lenalidomide is published in a special report Online First and in the July edition of The Lancet Oncology. About 2,000 multiple myeloma sufferers in the UK could benefit from the drug and improve their life expectancy pending a decision by The UK National Institute for Health and Clinical Excellence (NICE). Patients who have received two or more previous therapies could receive lenalidomide, and the cost of cycles beyond the twenty-sixth cycle of treatment would be met by the drug manufacturer.

Conference: Discovery Partnerships: Academia & Industrial Interactions
Opal Events is proud to present our next exciting conference Drug Discovery Partnerships: Academia & Industrial Interactions , to be held at the Hyatt Regency in Boston on October 28-30, 2009.
News of the day
Single-payer Advocates Challenge Democrats While Private Insurers Get Nervous
Democrats working feverishly on health care reform "face increasingly noisy protests from those on the left who complain that a national program like those in Europe has been excluded from the debate," The Washington Post reports.
Medical Devices

2009/039 NICE Guidance Recommends Lenalidomide For Multiple Myeloma

The National Institute for Health and Clinical Excellence (NICE) has published final guidance on the use of lenalidomide for multiple myeloma in people who have received at least one prior therapy. The new NICE guidance recommends lenalidomide in combination with dexamethasone as a treatment option for people with multiple myeloma who have received two or more prior therapies. The cost of the drug beyond 26 cycles (each of 28 days; normally a period of 2 years) will be met by the manufacturer, Celgene. For those patients who have not received two or more prior therapies, but are currently receiving lenalidomide, the independent Appraisal Committee has recommended they have the option to continue treatment until they and their clinician consider it appropriate to stop. Professor Peter Littlejohns, Clinical and Public Health Director at NICE said: "Multiple myeloma is a type of cancer that develops from cells in the bone marrow and there is currently no cure for the disease, only treatments to stop the progress of the condition and help relieve symptoms. It is an uncommon cancer, with less than 4000 new cases per year in the UK. "Following a proposal from the manufacturer of lenalidomide, where they bear the costs of the drug beyond 26 cycles (normally for a period of 2 years), the independent Appraisal Committee was able to recommend lenalidomide as treatment option for multiple myeloma in people who have received two or more prior therapies. The Committee also accepted that lenalidomide fitted NICE"s criteria for allowing its advisory bodies greater flexibility when making recommendations on the use of end of life treatments. "NICE already recommended bortezomib (Velcade) in October 2007 under a risk sharing scheme for patients who are experiencing their first relapse and publication of this new NICE guidance is good news for patients who have already tried other chemotherapy regimens." National Institute for Health and Clinical Excellence


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009